Literature DB >> 10799858

Effects of continuous exposure to stromal cell-derived factor-1 alpha on T cell rolling and tight adhesion to monolayers of activated endothelial cells.

J M Kantele1, S Kurk, M A Jutila.   

Abstract

Immobilized stromal cell-derived factor-1 alpha (SDF-1 alpha) has been shown to induce tight adhesion of T cells to purified ICAM-1 in assays done under flow conditions. In this study, we show that soluble SDF-1 alpha induced a rapid (within 20 s) cessation of rolling and tight adhesion of >90% of the rolling T cells on monolayers of activated endothelial cells under similar flow. Within 4 min, the T cells had either started to migrate between the endothelial cells or re-entered the rolling and circulating lymphocyte pool. This deadherence of the firmly bound cells, with either ensuing transmigration or continued rolling, was most likely due to desensitization of lymphocytes to the continuously present SDF-1 alpha. The released rolling lymphocytes could still respond to other activating signals by a second round of tight adhesion. Pretreating the lymphocytes with pertussis toxin almost completely blocked the effect of the chemokine, confirming that the induction of firm adhesion was due to the function of the chemokine on the lymphocytes and not the endothelial cells. Pretreating the endothelium with SDF-1 alpha did not lead to firm adhesion of subsequently added lymphocytes, also indicating that the effect was due to soluble, not endothelially bound, chemokine. Blocking experiments showed that the same molecules mediated rolling before and after SDF-1 alpha-induced tight adhesion. This is the first study to demonstrate the effect of soluble SDF-1 alpha on T cell rolling on an endothelial cell monolayer. The data broaden our understanding of the stimulatory factors directing the firm adhesion and ensuing transmigration of leukocytes into tissues through activated endothelium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10799858     DOI: 10.4049/jimmunol.164.10.5035

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Real-time imaging of lymphocytes in vivo.

Authors:  Michael D Cahalan; Ian Parker; Sindy H Wei; Mark J Miller
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

Review 2.  Stem cell-based therapies in ischemic heart diseases: a focus on aspects of microcirculation and inflammation.

Authors:  Junxi Wu; Jun Li; Nannan Zhang; Cuihua Zhang
Journal:  Basic Res Cardiol       Date:  2011-03-23       Impact factor: 17.165

Review 3.  Pathophysiology and neuroprotection of global and focal perinatal brain injury: lessons from animal models.

Authors:  Luigi Titomanlio; David Fernández-López; Lucilla Manganozzi; Raffaella Moretti; Zinaida S Vexler; Pierre Gressens
Journal:  Pediatr Neurol       Date:  2015-01-31       Impact factor: 3.372

4.  Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Authors:  Jehonathan H Pinthus; Tova Waks; Victoria Malina; Keren Kaufman-Francis; Alon Harmelin; Itzhak Aizenberg; Hannah Kanety; Jacob Ramon; Zelig Eshhar
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

5.  Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection.

Authors:  R Tanaka; A Yoshida; T Murakami; E Baba; J Lichtenfeld; T Omori; T Kimura; N Tsurutani; N Fujii; Z X Wang; S C Peiper; N Yamamoto; Y Tanaka
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Stromal-derived factor-1 and its receptor, CXCR4, are constitutively expressed by mouse liver sinusoidal endothelial cells: implications for the regulation of hematopoietic cell migration to the liver during extramedullary hematopoiesis.

Authors:  Mayela Mendt; Jose E Cardier
Journal:  Stem Cells Dev       Date:  2012-01-26       Impact factor: 3.272

7.  The SDF-1 3'A genetic variation is correlated with elevated intra-tumor tissue and circulating concentration of CXCL12 in glial tumors: a study on Iranian anaplastic astrocytoma and glioblastoma multiforme patients.

Authors:  Seyyed Reza Moosavi; Hossein Khorramdelazad; Masoud Amin; Shirin Fatahpoor; Mozhgan Moogooei; Mojgan Noroozi Karimabad; Mohamadreza Jamali Paghale; Alireza Vakilian; Gholamhossein Hassanshahi
Journal:  J Mol Neurosci       Date:  2013-01-20       Impact factor: 3.444

Review 8.  Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.

Authors:  Victoria Hillerdal; Magnus Essand
Journal:  BioDrugs       Date:  2015-04       Impact factor: 5.807

9.  The CXCL12gamma chemokine displays unprecedented structural and functional properties that make it a paradigm of chemoattractant proteins.

Authors:  Patricia Rueda; Karl Balabanian; Bernard Lagane; Isabelle Staropoli; Ken Chow; Angelique Levoye; Cedric Laguri; Rabia Sadir; Thierry Delaunay; Elena Izquierdo; Jose Luis Pablos; Elena Lendinez; Antonio Caruz; Diego Franco; Françoise Baleux; Hugues Lortat-Jacob; Fernando Arenzana-Seisdedos
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

10.  Natural nitration of CXCL12 reduces its signaling capacity and chemotactic activity in vitro and abrogates intra-articular lymphocyte recruitment in vivo.

Authors:  Rik Janssens; Anneleen Mortier; Daiane Boff; Vincent Vanheule; Mieke Gouwy; Charlotte Franck; Olav Larsen; Mette M Rosenkilde; Jo Van Damme; Flávio A Amaral; Mauro M Teixeira; Sofie Struyf; Paul Proost
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.